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Abstract
Background: Mental illness is highly prevalent among prisoners. Although psychotropic medicines can ameliorate
symptoms of mental illness, prescribers in prisons must balance clinical needs against risks to safety and security.
Concerns have been raised at the large number of prisoners reportedly receiving psychotropic medicines in
England. Nonetheless, unlike for the wider community, robust prescribing data are not routinely available for
prisons. We investigated gender-specific patterns in the prevalence and appropriateness of psychotropic prescribing
in English prisons.
Methods: We studied 6052 men and 785 women in 11 prisons throughout England. This represented 7.9 % of
male and 20.5 % of female prisoners nationally. Using a cross-sectional design, demographic and prescription data
were collected from clinical records of all prisoners prescribed psychotropic medicines, including hypnotic,
anxiolytic, antipsychotic, anti-manic, antidepressant and Central Nervous System stimulant medications. Percentages
and 95 % CIs were used to estimate the prevalence of prescribing. The Prescribing Appropriate Indicators tool was
used to determine appropriateness. Prevalence Ratios (PR) were generated to make age-adjusted comparisons
between prisoners and the general population using a dataset supplied by the Clinical Practice Research Datalink.
Results: Overall, 47.9 % (CI 44.4–51.4) of women and 16.9 % (CI 16.0–17.9) of men in prison were prescribed one or
more psychotropic medicines. Compared with the general population, age-adjusted prescribing prevalence was six
times higher among women (PR 5.95 CI 5.36–6.61) and four times higher among men (PR 4.02 CI 3.75–4.30).
Undocumented or unapproved indications for prescriptions, not listed in the British National Formulary, were
recorded in a third (34.7 %, CI 32.5–37.0) of cases, most commonly low mood and personality disorder.
Conclusions: Psychotropic medicines were prescribed frequently in prisons, especially among women, and for a
wider range of indications than are currently recommended. These findings raise questions about whether the
prescribing of psychotropic medicines in prisons is wholly appropriate and proportionate to the level of clinical
need. Prisons need to develop a wider array of treatment responses, other than medicines, to effectively tackle
mental illness, challenging behaviours and distress.
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Background
Prisoners have multiple, complex health needs, with the
prevalence of mental illness greatly elevated [1, 2]. Indi-
viduals presenting with mental illness may require treat-
ment with psychotropic medicines such as
antidepressants, antipsychotics and antimanic drugs. Ap-
propriate use of psychotropic medicines has been shown
to improve symptoms and reduce relapse rates in disor-
ders including depression [3], bipolar disorder [4, 5] and
schizophrenia [6]. Furthermore, a recent study demon-
strated that, among patients prescribed antipsychotics
and antimanic drugs, incidence of violent crime fell dur-
ing periods of medication use [7]. Nonetheless, due to
the complex interplay between clinical, social and situ-
ational factors, making prescribing decisions in prison
can be extremely challenging [8]. Guidance issued by the
UK’s professional body for general practitioners has
strongly emphasised the need to consider safety and se-
curity risks when prescribing in prisons, citing increased
risks of illicit substance misuse and trading, comorbidity,
self-harm and suicide [9].
It is difficult to ascertain a clear picture of psycho-
tropic prescribing patterns in prisons. In England, robust
data, with appropriate comparators, are routinely avail-
able on medicines prescribed in the community (via ser-
vices such as http://www.nhsbsa.nhs.uk/3230.aspx), but
prisons are not included. The Chief Inspector of Prisons
has expressed concern at the large number of prisoners
receiving psychotropic medicines, particularly women
[10]. In spite of such concerns, the last national survey
reporting on psychotropic prescribing in prisons was
conducted over fifteen years ago [11]. Since then, the
prison population has increased significantly, there have
been major organisational changes to the delivery of
prison healthcare, and new psychotropic drugs have ar-
rived onto the market.
Studies conducted in Switzerland [12], France [13],
Norway [14, 15] and the USA [16, 17] have indicated
that psychotropic prescribing prevalence is elevated in
prisons compared to the general population. This could
simply be attributed to the higher prevalence of mental
illness among prisoners. Indeed, it has been estimated
that overall rates of mental illness are between 3 and 4
times higher in prison than in the wider community,
although this varies for specific demographic groups and
diagnoses [2]. For example, psychosis is prevalent among
3.7 % of adult prisoners compared with 0.4 % in the gen-
eral population [18]. However, the relationship between
psychotropic prescribing and mental illness is not en-
tirely straightforward: whilst some patients may receive
non-pharmacological treatments for mental illness,
others may be prescribed psychotropic drugs ‘off label’
for reasons other than mental illness; for example, low
dose amitriptyline (a tricyclic antidepressant) is
sometimes used to treat neuropathic pain, but has no
license for that [19]. Furthermore, whilst some studies of
prescribing in prison have provided comparison data
from the wider community (and other settings) [12, 14],
none have adequately accounted for age and sex differ-
ences between populations. Such factors all add to the
difficulty of comparing psychotropic prescribing between
different settings and assessing whether prescribing in
prisons is wholly proportionate to clinical need.
Building on our previous study in a single, though
large, region of England [20] we conducted a national
study to investigate the prevalence and appropriateness
of psychotropic prescribing in English prisons to further
our understanding of this important and complex area
of clinical practice. Specifically, we hypothesised that
psychotropic prevalence for both men and women
would be significantly higher among prisoners than in
the general population, after accounting for age differ-
ences. In addition, we predicted that psychotropic pre-
scribing prevalence would be significantly higher among
female than male prisoners.
Methods
Prisons and participants
A cross-sectional study using patient clinical records
was conducted. In total, 6052 male and 785 female pris-
oners were surveyed from eleven prisons. Based on
prison population statistics from the final week of the
survey, the final sample represented approximately 7.9 %
of the male and 20.5 % of the female prisoner population
at that time. Two female prisons were included as well
as the following male prisons: three adult local prisons,
which accept convicted and unconvicted men directly
from court and make up approximately half of the
prison estate; three training prisons, which accept con-
victed and sentenced prisoners and offer rehabilitative-
oriented work and education programmes; two young
offender institutions, which accept 18–21 year olds; and
an open prison, which have minimal security restric-
tions. These prisons were geographically spread across
England and were recruited to represent a range of
prisoner populations, including adults, young offenders
(18–21 years) and both sentenced and un-convicted
prisoners. No high security prisons, which hold
prisoners requiring the most secure settings were
available to participate in the study.
For the purposes of generating point-prevalence pre-
scribing estimates, a ‘census day’ was selected for each
participating prison, all between November 2012 and
July 2013. Logistical reasons concerning data collection
precluded selecting the same census day for all eleven
sites, Census days were arranged on a pragmatic basis,
based on when it was at convenient for the researcher to
visit the prison and access clinical and prescribing
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records. Healthcare staff were aware that there would be
a researcher visiting the department during these times.
Inclusion criteria for the study were (i) aged 18 years
and over and (ii) in custody on the establishment’s census
day. Approvals were obtained from an NHS research eth-
ics committee (NHS NRES Committee North East - York,
Ref: 09/H0903/54), the National Offender Management
Service and each provider healthcare organisation.
Approval to access clinical records without consent, in the
public interest, was granted by the Ethics and Confidenti-
ality Committee, on behalf of the National Information
Board, under Section 251 of the NHS Act 2006. Patient
identifiable data were accessed onsite at each individual
prison only for the purpose of extracting relevant pre-
scribing and accompanying clinical data; all data were
immediately anonymised and no patient identifiable data
were recorded for research purposes. Information about
the study was displayed in prisons in multiple languages
in advance of census days. Individuals who did not wish to
participate were able to ‘opt-out’ by informing a member
of healthcare staff. Those who declined were recorded and
individual clinical records for these patients were not
accessed as part of the research. A research advisory group
of ex-prisoners met throughout the project, advising on
study design, methodology and dissemination activities.
The group was comprised of members who had previous
experience of serving on a research user group related to
mental health, suicide and self-harm, plus additional
members recruited separately via personal contacts of
existing members. The group included seven regular
members, both men and women all of whom had experi-
ence of (a) imprisonment and (b) accessing health services
in prison.
Prison data collection
The primary outcome measure was the prevalence of
psychotropic medication prescribing. Aggregate popula-
tion counts for each census day were generated to pro-
vide denominators for calculating prescribing prevalence
values. These estimates were stratified by age, gender,
ethnicity and legal status (sentenced vs. un-sentenced).
Electronic clinical information systems and/or paper
records were examined to identify all patients with a
current prescription for at least one psychotropic medi-
cation. Psychotropic medicines were defined as any
medication listed in subchapters 4.1–4.4 of the British
National Formulary (BNF) [21], including the following
medicines: hypnotics and anxiolytics (chapter 4.1), which
can be used to treat anxiety and sleep disorders; antipsy-
chotics and anti-manics (4.2), used to treat psychoses,
mood instability and related disorders; antidepressants
(4.3), used to treat depressive and anxiety disorders; and
CNS stimulants (4.4), used to treat attention deficit
hyperactivity disorder. The BNF is a pharmaceutical
reference book of medicines available on the NHS and is
widely used by pharmacists, prescribers and other
healthcare professionals for guiding the prescription,
dispensing, and administration of medicines.
For each prisoner prescribed at least one psychotropic
medication on the census day we extracted demographic
and prescription data. Demographic data included
gender, legal status, ethnicity and year of birth. We
collected the following details for all psychotropic pre-
scriptions: drug name (active ingredient), prescribed
daily dose, formulation, and indication (symptoms and/
or diagnosis). Additionally, we recorded the drug names
of all current prescriptions for non-psychotropic medi-
cines. Data were collected retrospectively, using informa-
tion that had been prospectively recorded (at the time of
clinical events, such as consultations and/or prescribing)
in clinical records. Community clinical records were not
available, therefore only data recorded from the time the
individual entered custody were considered.
To assess prescribing appropriateness, we used the
Prescribing Appropriateness Indicators (PAI), a set of
standardised, validated indicators, designed specifically
for use with clinical records [22]. The PAI has been vali-
dated for use in primary care populations (refs), al-
though not prisons specifically. To streamline data
collection, we discussed the nine items of the PAI and
identified a subset of four items deemed most relevant
to psychotropic prescribing. These were: the indication
for the drug is recorded and upheld in the BNF (PAI 1);
a generic (non-branded) product is prescribed if one is
available (PAI 2); if a potentially hazardous drug-drug
combination is prescribed, the prescriber shows know-
ledge of the hazard (PAI 3); and if the total daily dose is
outside the range stated in the BNF, either higher or
lower, the prescriber gives a valid reason (PAI 4). For
each individual psychotropic prescription, we recorded
whether or not each criterion was met. Some indicators
in the PAI refer to indications and dose ranges listed for
individual medicines listed in the BNF, based on infor-
mation in manufacturers’ Summaries of Product
Licences and related marketing authorisations. In
addition to licensed uses of medicines, certain
unlicensed uses are also listed in the BNF, although these
carry the caveat of increased professional responsibility
and liability for prescribers [21]. The five PAI items that
were not used addressed prescribing drugs of limited
value, cost, dosing frequency, treatment duration and
prescribing for hypertension. We determined that the
first four of these were more detailed than was necessary
for the purposes of this particular study, whilst the fifth
was clearly not applicable. The indicators within the PAI
are designed to be applied individually rather than ag-
gregated as a total score, therefore this approach did not
affect the validity of the items we did use.
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General population comparison dataset
For comparative purposes, we used a dataset supplied by
the Clinical Practice Research Datalink (CPRD) on a
broadly representative national sample of patients regis-
tered with general practices in the general population. In-
clusion criteria for CPRD patients were: (i) aged 18 years or
over and (ii) registered with a general practice within
England or Wales continuously during the eligibility period.
The CPRD supplied aggregate patient counts for (i) all
patients who met the inclusion criteria, for use as de-
nominators and (ii) all patients prescribed at least one
psychotropic medicine during the eligibility period. All
counts were stratified by gender and age group.
Individual-level data were necessary to generate point
prevalence estimates of psychotropic prescribing on a
single census day, namely 30 July 2010. These data had
already been obtained under the terms of a free license
scheme, in advance of the prison data collection. The
specific terms of the CPRD licence scheme (a 100,000
case limit) precluded us obtaining individual-level data
for all those patients prescribed psychotropic medicines
(n = 415,380); instead, we requested data for a sub-
sample of 30,602 patients. This included all patients
prescribed CNS stimulants (BNF subchapter 4.4) and a
random sample of: 10,000 patients prescribed hypnotics
and anxiolytics (4.1); 10,000 patients prescribed anti-
psychotic and anti-mania drugs (4.2); and 10,000
patients prescribed antidepressants (4.3). Demographic
data included gender and year of birth; ethnicity, how-
ever, was incompletely recorded. Data pertaining to all
medicines prescribed during the observation period were
supplied, including drug name, formulation, dose,
frequency, prescription date and duration.
Denominators for calculating point prevalence
estimates, proportionate to the subsample for whom
individual-level data were available, were generated using
the following method. Individual-level data were avail-
able for 7 · 4 % (n = 30,602) of all patients prescribed
psychotropic medicines during the eligibility period (n =
415,380). Given that we had individual-level data on all
patients prescribed CNS stimulants, we were able to use
these directly in combination with the aggregate patient
counts supplied by CPRD for use as denominators to
generate point-prevalence estimates of prescribing (i.e.
number of patients prescribed CNS stimulants/ total
number of patients = prevalence). However, given that
we had only a subsample of patients prescribed psycho-
tropic medicines in BNF subchapters 4 · 1–4 · 3, it was
not possible to use the counts supplied by CPRD in a
direct manner to generate point prevalence estimates for
psychotropic medicines other than CNS stimulants.
Thus, we required a method to generate population
denominators proportionate to the sample of patients
for whom we had individual-level data. If we let the total
number of CPRD patients within the eligibility period be
sample a, then among them the sample of patients pre-
scribed at least one psychotropic medicine will be
sample b. In turn, the random sample of patients among
sample b for whom individual-level data were provided
will be sample c.
To generate ‘proportionate population denominators’
(sample d), we applied the following formula to each
age/sex stratum (by BNF subchapter): a × (c/b) = d.
Sample d provided the denominators for the community
sample in this study. The denominators derived via this
process are provided in Additional file 1: Table S1.
Statistical analysis
Analyses were performed using version 12 of Stata
software for Windows [23]. We calculated point preva-
lence values (as percentages) for psychotropic prescrib-
ing, and their 95 % confidence intervals using the
Wilson method [24], stratified by BNF chapter, for both
the prison population and the general population. These
values were stratified by gender throughout because of
the marked heterogeneity between the female and male
prisoner populations. Prevalence ratios (PRs) were
generated to compare prescribing prevalence between
prisoners and the general population using the ‘ir’ com-
mand in Stata, which applies asymptotic approximations
to generate 95 % confidence intervals. To account for
the fact that prisoners are generally younger than the
general population, the PRs were indirectly standardised
for age using the CPRD dataset as the standard popula-
tion. For disclosure control purposes, values of cells
where the value was <5 were suppressed.
Percentages and their 95 % confidence intervals were
used to describe the likelihood of psychotropic prescrip-
tions issued in prison meeting each of the PAI items. To
determine the proportion of prescriptions prescribed within
the range stated in the BNF (PAI 4), we calculated the pre-
scribed daily dose and compared this to the dose stated in
the BNF. Where doses for an individual medicine differed
by indication (for example, amitriptyline is prescribed at
lower doses for pain than as an antidepressant), the dose
for the specific indication stated in the prisoner’s clinical
record was used. If there was an invalid indication, or no
indication, stated, the smallest minimum and largest max-
imum values provided across all indications for that medi-
cine were used instead. We also identified the drugs most
frequently associated with an inappropriate indication or
no indication recorded, potentially hazardous drug-drug in-
teractions and prescribed daily doses outside the range
stated in the BNF. Where there were missing data, cases
with missing values were excluded from analyses involving
those particular variables as outcomes or predictors (list-
wise deletion).
Hassan et al. BMC Psychiatry  (2016) 16:346 Page 4 of 10
Results
The study dataset consisted of a total of 6052 men and
785 women from 11 prisons (Table 1). Based on prison
population statistics during the final month of data col-
lection (July 2013), this sample represented 7.9 % of the
male and 20.5 % of the female prison population of
England. The great majority of prisoners (86.3 %) were
sentenced and 82.9 % were of White ethnicity.
Figure 1 shows the relationship between age and psy-
chotropic prescribing, grouped by setting (prison vs.
general population) and gender. Perhaps the most note-
worthy feature is the strikingly high prescribing preva-
lence observed among female prisoners, as compared
with all other groups. In prison, 47.9 % (CI 44.4–51.4) of
women and 16.9 % (CI 16.0–17.9) of men were pre-
scribed at least one psychotropic medicine (Table 2 and
Fig. 2); women were almost three times more likely than
men to be prescribed psychotropics (PR 2 · 7 CI 2 · 4–3 ·
0). Fig. 1 indicates that psychotropic prescribing among
prisoners peaked in the middle age bands (25–54 years),
whilst prescribing observed in the general population ap-
peared to show a linear increase with age. This contrast
was particularly apparent for women in prison, with over
half of women aged 35–54 being prescribed psycho-
tropic medicines compared with less than 10 % of
women in the general population.
Table 2 shows that, compared with patients in the gen-
eral population, rates of psychotropic prescribing in
prison were 4.0 (CI 3 · 8–4 · 3) times higher among men
and 6 · 0 (CI 5 · 4–6 · 6) times higher among women after
adjustment for age. The most commonly prescribed
psychotropic medicines in prison were antidepressants,
both for men and women. In total, 1175 (67.5 %) of the
1740 separate prescriptions for psychotropic medicines
identified in prison, were for antidepressants (Table 3).
Collectively, the class of medicines known as selective
serotonin reuptake inhibitors accounted for the greatest
percentage of antidepressant prescriptions in prison
(45.1 %, n = 530). Tricyclic antidepressants accounted for
a lower proportion of antidepressant prescriptions in
prison than in the community (14.9 % vs. 26.5 %; PR
0.56, 95 % CI 0.49 to 0.65). Individually, mirtazapine was
the most frequently prescribed antidepressant in prison
(35.2), but accounted for just 8.3 % of community anti-
depressant prescriptions (PR 4.26, 95 % CI 3.87 to 4.69).
Women were eight times more likely than men to be
prescribed hypnotic and anxiolytic medicines (PR 7 · 84
CI 5 · 42–11 · 36). As Table 4 shows, diazepam accounted
for half (53.4 %) of all hypnotic and anxiolytic prescrip-
tions in prison, but only 21.5 % in the community. Pre-
scribing rates for antipsychotics and CNS stimulants
were much higher among prisoners than primary care
patients in the general population (Table 2). Among an-
tipsychotics and antimanics drugs, second generation
antipsychotics were the most frequently prescribed drugs
(76.1 %, n = 293), followed by antimanics (14.6 %, n = 56)
and first generation antipsychotics (8.6 %, n = 33). Olan-
zapine and quetiapine, collectively accounted for over
half of all prescriptions within this BNF chapter (Table 3).
There were 49 instances of CNS stimulant prescribing in
prison, 90.9 % (n = 40) of which were prescribed to treat
Attention Deficit Hyperactivity Disorder (ADHD). Me-
thylphenidate accounted for 75.5 % (n = 37) of prescrip-
tions and atomoxetine accounted for the remaining
24.5 % (n = 12). Among men, the majority of prescrip-
tions for CNS stimulants came from youth offender
establishments (72.7 %, n = 32).
Overall, valid (BNF listed) indications for psychotropic
drugs were recorded in 65.3 % (63.0–67.5 %) of cases:
prescriptions issued to women were slightly more likely
to be accompanied by a valid indication than those is-
sued to men (PR 1.18 CI 1.11–1.27; Table 4). The most
common invalid indications recorded for antidepressant
and antipsychotic prescriptions were low mood (n = 94)
and personality disorder (n = 54), respectively. Other in-
valid diagnoses commonly recorded included anxiety, in-
somnia and agitation.
In 93 % of cases overall (93.5 % and 91.4 % for men
and women respectively), the total daily dose prescribed
was within the range specified in the BNF, thus meeting
the PAI indicator. By some margin, the medicine most
commonly prescribed at a sub-therapeutic dose was the
antipsychotic quetiapine (37 % of cases); indeed, the me-
dian prescribed dose across all quetiapine prescriptions
was 300 mg (37.5 % of the BNF maximum). One in five
Table 1 Prisoner sample characteristics
N Percent n Percent
Gender Prison type
Male 6052 88.5 Local 2192 32.1
Female 785 11.5 Training 2188 32.0
Legal status Open 598 8.7
Sentenced 5898 86.3 Youth Offender 1074 15.7
Unsentenced 924 13.5 Female 785 11.5
Othera 15 0.2
Age group Ethnicity
18–24 2012 29.4 White 5620 82.9
25–34 1981 29.0 Black 574 8.5
35–44 1387 20.3 Asian 348 5.1
45–54 877 12.8 Mixed 182 2.7
55–64 340 5.0 Other 57 0.8
65–74 177 2.6
75+ 61 0.9
Total 6837 100
a Includes civil prisoners and detainees
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(19.4 %) antipsychotic prescriptions were issued at a
sub-therapeutic dose, lower than recommended to treat
psychoses. Only six cases were identified where the pre-
scribed dose exceeded the maximum recommended
dose. Three of these prescriptions were for duloxetine, a
type of antidepressant (usually prescribed at 60 mg once
daily).
Potentially hazardous drug-drug interactions involving a
psychotropic medication, and with no evidence of ac-
knowledgement by the prescriber, were noted in 15.7 % of
prescriptions. The most frequently observed interactions
were: antipsychotics and antiepileptics (n = 33); SSRI and
non-steroidal anti-inflammatory drugs (n = 31); SSRI and
antiepileptics (n = 27); and antipsychotics and methadone
(n = 24). Among those prescribed antipsychotics,
hazardous interactions were slightly more common
among women than men (PR 1.17 CI 1.01–1.35).
Discussion
The findings of this study showed a high prevalence of
psychotropic prescribing in English prisons, with 47.9 %
of women and 16.9 % of men prescribed at least one
psychotropic medicine. After adjustment for age, the
prevalence of psychotropic prescribing was six times
higher among women and four times higher among
men, when compared with the general population. Our
findings are consistent with previous studies, which have
reported frequent psychotropic prescribing among pris-
oners in England [11, 20], other Western European
countries [12–15] and the USA [16, 17]. Whilst
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Fig. 1 Prison and community psychotropic point-prevalence prescribing rates, by age group and sex
Table 2 Crude and age-adjusted comparisons of prison sample versus general population psychotropic prescribing point prevalence
estimates by gender and BNF subchapter
BNF chapter Prison Community (ref.) PR (95 % CI)
% N % n Crude Age adjusted
Men
Hypnotics and anxiolytics 1.0 62 1.4 2082 0.74 (0.56–0.96) 1.27 (0.97–1.64)
Antipsychotics and antimanics 4.3 258 1.1 2430 3.67 (3.21–4.18) 4.81 (4.21–5.50)
Antidepressants 13.2 801 4.6 4183 2.87 (2.66–3.10) 4.16 (3.84–4.50)
CNS stimulants 0.7 44 0.0 457 22.57 (16.17–30.79) 12.99 (9.48–17.80)
Any 16.9 1024 5.8 6781 2.90 (2.71–3.10) 4.02 (3.75–4.30)
Women
Hypnotics and anxiolytics 7.9 62 2.5 3756 3.11 (2.38–4.00) 7.40 (5.73–9.55)
Antipsychotics and antimanics 11.7 92 1.6 3295 7.49 (6.01–9.22) 12.74 (10.30–15.76)
Antidepressants 41.1 323 10.0 8858 4.09 (3.65–4.58) 5.55 (4.96–6.22)
CNS stimulants 0.5 <5a 0.0 335 22.29 (6.04–57.61) 19.01 (7.07–51.10)
Any 47.9 376 11.8 12146 4.05 (3.65–4.49) 5.95 (5.36–6.61)
PR Prevalence Ratio
a N suppressed due to small <5 cell count
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psychotropic drugs can help to manage symptoms of
mental illness, they have also been linked with addiction,
unpleasant side effects, physical health risks and even
early mortality [25, 26]. Thus, unnecessary or inappro-
priate prescribing can carry clinical, as well as cost, im-
plications. It is well-established that prisoners have
raised prevalence of mental disorder, three to four times
higher than in the general population [2]. Nonetheless,
the proportion of prisoners who were prescribed psycho-
tropic medicines in this study, especially among women,
appeared to be disproportionately elevated in compari-
son with the wider community. Furthermore, a third of
prescriptions for psychotropic medicines issued in prison
were prescribed for undocumented or unapproved indi-
cations, not listed in the BNF.
The prevalence of psychotropic prescribing was strik-
ingly high among women in prison; indeed, in the mid-
dle age bands (35–54 years), the majority of women
were prescribed such medicines. Several factors could be
involved. First, a proportion of prescribing will be attrib-
utable to the higher prevalence of mental illness seen
among women in prison. Second, due to a variety of
clinical, social and situational factors, women are said to
be differently and disproportionately affected by impris-
onment [27]. Third, historically there has been a ten-
dency to over medicalise the social and behavioural
problems of women who offend [28]. Set in this wider
context, it is possible that medication has now become
the default treatment response not only to mental ill-
ness, but also challenging behaviours and distress.
Greater access to psychological therapies and support
for vulnerable individuals in custody could be possible
ways to reduce reliance on psychotropic medication.
Prescribing rates for CNS stimulants were much higher
among prisoners than primary care patients in the general
population. Whilst absolute numbers were small and con-
fidence intervals were wide, this finding does seem to be
broadly compatible with previous research, which has in-
dicated that ADHD is disproportionately more common
among offenders, both in childhood and in adults [29]. As
with other mental illnesses, medicines may be considered
an integral part of effective treatment packages for individ-
uals with ADHD in prison, enabling greater engagement
with therapeutic and rehabilitative programs. Nonetheless,
given that drugs within this therapeutic class have a high
propensity for diversion, abuse and dependence, pre-
scribers should continue to exercise caution when pre-
scribing in prisons, especially where there is a history of
substance misuse [30].
In this study, it was not uncommon for psychotropic
medicines to be prescribed for a wider range of indica-
tions than is currently recommended, in particular for
low mood (rather than a formal diagnosis of depression)
and personality disorder. One possible explanation is
that prisons lack the precision to distinguish between,
and respond to, mental illness, distress and challenging
behaviours, not all of which should require treatment
with psychotropic medicines. Such patterns and pre-
scribing practices, whilst arguably concerning, may not
necessarily be unique to prisons. Indeed, whilst no drugs
are currently licensed for the treatment of personality
disorder, one study reported that four fifths of patients
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Fig. 2 Prison and community psychotropic point-prevalence
prescribing rates, by sex
Table 3 Top five most commonly prescribed psychotropic
medicines in prison (descending order), compared with the
community, by BNF subchapter and drug
Drug Prison % n Community % n
Hypnotics and anxiolytics
1 Diazepam 53.4 70 21.5 1376
2 Zopiclone 16.0 21 32.3 2067
3 Chlordiazepoxide 13.7 18 0.9 55
4 Promethazine 9.2 12 2.6 164
5 Melatonin 2.3 <5a 0.8 48
All 100 131 100 6395
Antipsychotics
1 Olanzapine 30.9 119 14.6 935
2 Quetiapine 28.6 110 12.7 812
3 Risperidone 10.1 39 9.0 573
4 Carbamazepine 9.4 36 21.2 1355
5 Chlorpromazine 2.6 10 2.9 186
All 100 385 100 6404
Antidepressants
1 Mirtazapine 35.2 413 8.3 1157
2 Citalopram 18.2 214 27.3 3826
3 Sertraline 13.0 153 7.4 1043
4 Fluoxetine 11.2 132 12.8 1801
5 Amitriptyline 8.8 104 16.7 2338
All 100 1175 100 14028
a N suppressed due to small <5 cell count
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with a primary diagnosis of personality disorder under the
care of community mental health services received psy-
chotropic medication [31]. Furthermore, we found that a
fifth of all antipsychotics were prescribed at sub-
therapeutic doses. Very few psychotropic prescriptions
exceeded the recommended dose range listed in the BNF.
This finding contrasts with a previous systematic review
of the literature on prescribing for prisoners which re-
ported concerns with excessive, rather than inadequate,
doses [32]. Unfortunately, the majority of the papers in-
cluded in the review were conducted in hospital settings,
rather than prisons, complicating interpretation.
This study benefits from two large samples of people
in prison and the general population, thereby increasing
the precision of our prevalence estimates, statistical
power and generalisability. Except for our own previous
work [20], no other studies have made robust, age-
adjusted comparisons of prescribing between prisons
and the general population; hence, previous studies have
probably underestimated any relative differences. None-
theless, it was not a random sample and not all prisoners
and prison types were included (e.g. high secure
prisons). Furthermore, CPRD data were based on pre-
scribing data that were approximately two years older
than the prison prescribing data that we collected.
Unfortunately, due to the study design, we could not ad-
just for the prevalence of mental illness. This limits the ex-
tent to which we can draw firm conclusions about
whether the prescribing of psychotropic medicines is
wholly appropriate and proportionate to the level of need.
This was a records-based study and limited to information
readily available in clinical notes. Clinical records are
regarded as a reliable source of information and have the
advantage of recording information in a prospective man-
ner, as clinical events occur. Nonetheless, it is possible that
certain diagnoses may have not been recorded or were
missed when extracting the information, retrospectively.
Also, due to differences in data types and collection
methods we could not make certain comparisons between
patients in prison with those in the general population. In
particular, although we were able to assess some aspects
of prescribing appropriateness among prisoners, we could
Table 4 Proportion of prison prescriptions for psychotropic medications that met each PAI indicator by gender and BNF subchapter
PAI Indicatora, BNF Sub-chapter
Hypnotics &
anxiolytics
Antipsychotics &
antimanics
Antidepressants CNS Stimulants Any Psychotropic
% n % n % n % n % n
Men
1 Valid indicationb 90.5 57 50.5 141 61.8 512 90.9 40 62.0 758
2 Generic product 100 64 97.5 273 100 832 100 44 99.4 1222
3 No drug-drug interaction 93.7 59 80.7 221 87.1 714 93.2 41 86.2 1043
4 Valid dose range 91.7 55 81.7 227 97.5 809 95.4 41 93.5 1132
Women
1 Valid indicationb 85.7 54 53.9 55 76.8 262 100 5 73.4 378
2 Generic product 98.5 66 99.1 104 100 343 100 5 99.6 522
3 No drug-drug interaction 100 59 69.0 69 84.4 286 100 5 83.4 423
4 Valid dose range 98.3 59 77.9 81 94.1 321 100 5 91.4 466
a Key
PAI Indicator
1 The indication for the drug is recorded and upheld in the BNF.
2 A generic product is prescribed, if one is available.
3 If a potentially hazardous drug-drug combination is prescribed, the prescriber shows knowledge of the hazard.
4 If the total daily dose is outside the range stated in the BNF or SPC, the prescriber gives a valid reason.
b Key
BNF sub-chapter Valid indications (licensed and unlicensed), as listed in the BNFa
Hypnotics & anxiolytics Anxiety, insomnia, alcohol dependence, benzodiazepine dependence and allergies.
Antipsychotics and antimanics Schizophrenia, psychosis, bipolar disorder, epilepsy, severe aggression or agitation.
Antidepressants Depression, anxiety, bipolar disorder, obsessive compulsive disorder and post-traumatic stress disorder.
CNS Stimulants Attention Deficit Hyperactivity Disorder
Note: Denominators vary due to missing data (handled via listwise deletion)
a Note that not all indications are valid for all drugs in each BNF subchapter
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not do this for community patients, without gaining more
detailed access to their clinical records. Thus we cannot
know whether the issues identified here were necessarily
unique to prisons. CPRD data did not include the small
proportion of psychotropic prescriptions issued in second-
ary care settings, resulting in an underestimate of pre-
scribing prevalence in the general population. Finally, in
focusing on hypnotic, anxiolytic, antipsychotic, antimanic,
antidepressant and CNS stimulant medicines, we inevit-
ably missed a proportion of other medicines which may
be prescribed to treat mental illness. This included certain
antiepileptic drugs, which whilst primarily used to treat
epilepsy, may also be used to treat bipolar disorder [21].
Conclusions
In summary, this study has generated robust prevalence
estimates of psychotropic prescribing for a national sam-
ple of male and female prisoners, compared with the
general population. Psychotropic medicines were pre-
scribed more frequently in prisons, especially among
women, and for a wider range of indications than are
currently recommended. The results of this study draw
attention to disparities and potentially inappropriate pre-
scribing practices in prisons, which are a critical setting
for influencing wider public health. The majority of pris-
oners serve relatively short sentences (less than six
months) before being returned to the community. Thus,
the treatment of prisoners with mental illness carries im-
plications not only for prescribers in prisons, but also
those working with ex-prisoners in the wider commu-
nity. Further research is needed to understand the rea-
sons why clinicians are prescribing against current
guidelines, whether or not this is unique to prisons, and
to determine any clinical implications for future mental
and physical health. To reduce reliance on medication,
prisons may need to develop a more comprehensive
array of treatment responses to address mental illness,
challenging behaviours and distress.
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